2023-508587-29-00
CTIS ↗
201
Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
pharma
Y-mAbs Therapeutics
Y-Mabs Therapeutics A/S
Y-mAbs Therapeutics trial registry — 1 ClinicalTrials.gov studies with program phase, status, and indication context.
New York, USA HQ
2015 Founded
68 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2015
- Employees
- 68
- Programs
- 1
- Drugs
- 5
- Patents
- 0
Y-mAbs Therapeutics clinical trials
Registry index of 1 ClinicalTrials.gov studies linked to Y-mAbs Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Y-mAbs Therapeutics trial registry — 1 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Y-mAbs Therapeutics.